Tesamorelin

Tesamorelin is a long-acting GHRH analog approved for reducing excess visceral fat in individuals with HIV-associated lipodystrophy. It has demonstrated targeted fat-reducing effects without direct growth hormone replacement.

Tesamorelin is approved by the FDA for use in HIV-associated lipodystrophy, which describes an abnormal distribution of fat that occurs as a side effect of the medications taken by people with HIV. Tesamorelin is being researched for potentially reducing visceral fat (the fat found around internal organs, such as the kidneys). Areas studied include: Age-related growth hormone decline; Improving sleep quality and recovery after workouts; General metabolic health.

Tesamorelin stimulates growth hormone release, which in turn increases fat breakdown, particularly visceral fat, which is the fat around inner organs such as the kidneys. This selective action reduces abdominal fat while preserving lean mass.

Side effects include injection site reactions, fluid retention, and mild joint discomfort. Tesamorelin may increase blood sugar in some individuals.

One commonly referenced research protocol is: Weeks 1-2: 0.5 mg every night; Weeks 3-4: 1 mg every night; Weeks 5 and beyond: 2 mg every night. Shown for education only; a licensed clinician should set any actual dose. See the dosing table.

Wipe the vial tops with alcohol, add bacteriostatic water slowly so it runs down the inside of the glass, then roll the vial gently until the powder dissolves; don’t shake it. See the step-by-step guide with diagrams for the pen and syringe methods.

There is no single correct amount. We recommend 2.1 mL: about 0.1 mL is lost during transfer, leaving roughly 2.0 mL of usable solution. You can add more or less (most peptide vials hold up to 3 mL); just enter the amount in the dose calculator. See the step-by-step mixing guide.

Tesamorelin is FDA-approved in the US for specific indications (status as of October 2026).